The next-generation TKI drug tucatinib, a TKI specific for targeting HER2, has shown significant efficacy when used in conjunction with trastuzumab and capecitabine for treating patients with BM resulting from HER2+ breast cancer, as evidenced by the findings of the phase III HER2CLIMB clinical trial. The gene discussed is ERBB2; the disease is breast carcinoma.